Symetis (Switzerland) a clinical-stage medical device company focused on a transcatheter aortic valve implantation, closed a $25.8M Series C financing. Participants include Endeavour Vision, NBGI Ventures, Truffle Capital, Novartis Venture Fund, Wellington Partners Venture Capital, Vinci Capital, Renaissance PME, Banexi Venture Partners and BiomedInvest.